Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia 2Primary Myelofibrosis 1Multiple Myeloma 1Leukemia, Monocytic, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Clonal Cytopenia of Undetermined Significance 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Cytarabine 58Etoposide 24Daunorubicin 22Filgrastim 18Idarubicin 16Mitoxantrone 13Busulfan 13tipifarnib 11fludarabine phosphate 10Gemtuzumab 10Cyclophosphamide 10Peripheral Blood Stem Cell Transplantation 9Flow Cytometry 9sargramostim 8Clofarabine 8Methotrexate 7Gene Expression Profiling 7Cyclosporine 7Topotecan 6Azacitidine 6valspodar 5alvocidib 5Granulocyte Colony-Stimulating Factor 5Antilymphocyte Serum 5aldesleukin 4Radiotherapy 4Observation 4Bortezomib 4Arsenic Trioxide 4Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Monocytic, Acute × enasidenib × Clear all
NCT05282459 2026-04-17

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Stanford University

Phase 1/2 Completed
17 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡